EpiCast Report: Breast Cancer (HER2-HER2+) - Epidemiology Forecast to 2023




$ 3995

In Stock


Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Prolonged exposure to endogenous and exogenous sex hormones, gene mutations, a family history of breast cancer, overweight and obesity, physical inactivity, a sedentary lifestyle, high alcohol consumption, early age at menarche (<12 years), late age at menopause (>55 years), and clinical factors, such as biopsy-confirmed atypical hyperplasia, and having a high breast tissue and bone density are all risk factors for breast cancer.


GlobalData epidemiologists forecast that the number of diagnosed incident cases of breast cancer in women in the 8MM is expected to grow to 1.21 million cases in 2023 at a rate of 4.23% per year during the forecast period. The number of five-year diagnosed prevalent cases in the 8MM is expected to increase by 43.0% over the next decade to 5.12 million cases in 2023.


GlobalDatas forecast is supported by at least 10 years of robust, country-specific historical data obtained from the WHO International Agency for Cancer Researchs (IARCs) SurvCan, the Surveillance of Epidemiology and End Results Program Cancer Statistics Review 1975-2009, EUROCARE-4, research articles published in peer-reviewed journals, and the IARCs Cancer Incidence in Five Continents Plus database, which provided detailed case segmentation by age and sex and is considered the gold standard for international comparison of country-specific data. Another strength of this analysis is that GlobalData epidemiologists compared the incident case projections with the estimates made by country-specific registries and the IARC, and found that the forecast numbers were in accordance with the international estimates.




  • The Breast Cancer (HER2-, HER2+) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for breast cancer in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). In addition, the report also includes a 10-year forecast for the incident and the five-year prevalent cases of breast cancer in women segmented by age (20 to =85 years), natural menopausal status, cancer stage at diagnosis (local, regional, distant, unstaged), and hormone receptor subtypes: ER+ and/or PR+, HER2-; ER-, PR-, HER2+; ER+ and/or PR+, HER2+; and ER-, PR-, HER2(triple negative).
  • The breast cancer epidemiology report is written and developed by Mastersand PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.


Reasons to buy


  • Develop business strategies by understanding the trends shaping and driving the global breast cancer market.
  • Quantify patient populations in the global breast cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups, menopausal status, cancer stage, and hormone receptor subtypes that present the best opportunities for breast cancer therapeutics in each of the markets covered.